School of Medicine researchers have designed a synthetic protein against COVID-19. Dr. Jay Kolls, John W. Deming Endowed Chair in Internal Medicine and lead author of the research, said the engineered protein, called MDR504, is designed to go to the lungs to neutralize the virus before it can infect lung cells. In addition to a treatment, the protein could be used as a pre- or post-exposure therapy for healthcare workers, first responders and vulnerable populations at high risk.

Dr. Richard Oberhelman and others at the School of Public Health and Tropical Medicine have partnered with local healthcare providers for a COVID-19 study of patients and healthcare workers in New Orleans as part of a larger Centers for Disease Control and Prevention effort to better understand the virus. The study will provide estimates of how many people in a given area have COVID-19 and overall infection rates over time. It will also examine geographic, demographic and clinical trends.

A team of researchers is studying how the coronavirus works and where and when it is shed through a $700,000 grant by the Centers for Disease Control and Prevention. What researchers find could help explain why COVID-19 is causing higher death rates among Black and Hispanic residents of New Orleans. Assistant Professor of Medicine Dr. Dahlene Fusco, who is part of the team, said researchers want to learn whether specific factors related to the virus or something within the host contribute to the higher fatality rate.

Tulane has joined other institutions across the globe in a trial of a drug, TL-895, to treat severe COVID-19 in hospitalized cancer patients. Dr. Nakhle Saba, associate professor of clinical medicine at the School of Medicine, is principal investigator of the trial. Saba said that data show 40% of COVID-19 patients with cancer required hospitalization, 20% developed severe respiratory illness, and 12% died within 30 days.

Nora Lustig, the Samuel Z. Stone Professor of Latin American Economics and director of the Commitment to Equity Institute at Tulane, organized networks of economists and researchers to examine Latin American countries’ COVID-19 situation and policy responses. One group’s work resulted in a partnership with the United Nations Development Program that focused on actionable items for governments, individuals and organizations to support countries’ populations.

Tulane Brain Institute faculty member and Assistant Professor of Psychology Jonathan Fadok is conducting research on panic disorder — one of the most common mental disorders in the United States, with nearly 5 percent of the population suffering attacks that cause extreme disruption in their daily lives. Fadok is working on the identification of neurobiological mechanisms through which the brain reacts to fearful stimuli. The research, funded by a $2.24 million grant from the National Institutes of Health, could provide new insights into post-traumatic stress disorder and panic disorder.